55477-09-3

Upstream product

• 52763-30-1 Abbott 41988 
• 60926-09-2 8-[4-(4-fluoro-phenyl)-1-methyl-butyl]-5,5-dimethyl-1,3,4,5-tetrahydro-2H-chromeno[4,3-c]pyridin-10-ol 

Downstream Products

• 64097-32-1 8-[4-(4-fluoro-phenyl)-1-methyl-butyl]-5,5-dimethyl-2-oxy-5H-chromeno[4,3-c]pyridin-10-ol 
• 55477-14-0 8-[4-(4-fluoro-phenyl)-1-methyl-butyl]-10-methoxy-5,5-dimethyl-5H-chromeno[4,3-c]pyridine 
• 55477-16-2 10-allyloxy-8-[4-(4-fluoro-phenyl)-1-methyl-butyl]-5,5-dimethyl-5H-chromeno[4,3-c]pyridine 

Relevant academic research and scientific papers

5H-[1]Benzopyrano[3,4-d]pyridines

5H-[1]Benzopyrano[3,4-d]pyridines represented by the formula STR1 wherein each R1 is loweralkyl, R2 is alkyl, cycloalkyl or STR2 wherein Y is a straight or branched chain alkylene group having from 1 to 10 carbon atoms and each Rsub

Cannabinoids. Synthesis and central nervous system activity of 8 substituted 10 hydroxy 5,5 dimethyl 5H [1]benzopyrano[4,3 c] pyridine and derivatives

8-(1,2-Dimethylheptyl)- and 8-[5-(4-fluorophenyl)-2-pentyl]-10-hydroxy- 5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridines (2a and 2b), their phenolic ester and ether derivatives, and their N-oxides were synthesized and evaluated in various CNS pharmacological tests in animals. 2a was found to be the most potent compound.